Abstract:4-anilinoquinazoline-based derivatives represent an attractive scaffold for small molecular EGFR-TKIs in the field of medicinal chemistry. A series of novel heterocyclic substituted derivatives have been designed, synthesized and evaluated their antitumor bioactivities as potential EGFR-TKIs. Most of the new compounds exhibited certain efficient inhibition potency for proliferation of a panel of five human cancer cells with IC50 values at the low micromolar level, and some of them possessed good broad-spectrum inhibition activities, compared to Gefitinib. Especially, the IC50 values of compound 21 against HepG2, A549, MCF-7, DU145 and SH-SY5Y cells were 4.61, 9.50, 9.80, 6.79 and 7.77 μM, respectively, which were much lower than those of Gefitinb. Furthermore, the highlighting compound 21 demonstrated excellent inhibition activity against EGFR-TK with the IC50 value of 3.62 nM, similar to that of Gefitinib(2.21 nM). The results of LDH release assay proved that compound 21 was anti-proliferative rather than cytotoxicity on HepG2 cells. Compound 21 were able to cause HepG2 cells to block in S phase and induce cell death mainly by apoptosis through a mitochondrial dependent pathway. Moreover, the assessment of MMP, the determination of intracellular free Ca2+ concentration, the production of ROS, and the effects on the activity of caspase-3 in a dose-dependent manner demonstrated that compound 21 induced cell apoptosis in HepG2 cells through the Ca2+/ROS-mediated mitochondria/caspase-dependent apoptosis pathway largely. These preliminary results evidenced that compound 21 could be a potential antitumor agent deserving further study.

Design, Synthesis and Anticancer Activity Evaluation of 4-(3-1h-indazolyl)amino Quinazoline Derivatives As PAK4 Inhibitors

Design, synthesis and anticancer activity evaluation of 4-(3-1f H -indazolyl)amino quinazoline derivatives as PAK4 inhibitors

Design, Synthesis and Biological Evaluation of 1-Phenanthryl-tetrahydroisoquinoline Derivatives As Novel P21-Activated Kinase 4 (PAK4) Inhibitors.

Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives As Potent and Selective P21-Activated Kinase 4 (PAK4) Inhibitors

Advances in the 1-Phenanthryl-tetrahydroisoquinoline Series of PAK4 Inhibitors: Potent Agents Restrain Tumor Cell Growth and Invasion

Design, Synthesis, Structure-Activity Relationships Study and X-ray Crystallography of 3-Substituted-indolin-2-one-5-carboxamide Derivatives As PAK4 Inhibitors.

Design, synthesis and biological evaluation of novel benzimidazole-derived p21-activited kinase 4 (PAK4) inhibitors bearing a 4-(4-methylpiperazin-1-yl)phenyl scaffold as potential antitumor agents

Design, synthesis and anti-tumor activity evaluation of 4,6,7-substitute quinazoline derivatives

3D-QSAR, Docking, and Molecular Dynamics Simulations Studies on Quinazoline Derivatives As PAK4 Inhibitors

Synthesis and anticancer activities of 4-(4-substituted piperazin)-5,6,7-trialkoxy quinazoline derivatives

Synthesis and Antitumor Activity Evaluation of 4,6-Disubstituted Quinazoline Derivatives As Novel Pi3k Inhibitors

Design, Synthesis and Biological Evaluation of Novel 2,4,6-Trisubstituted Quinazoline Derivatives As Potential Antitumor Agents

Synthesis and Antitumor Activity of Novel 4-Aminoquinazoline Derivatives Containing Benzothiazole

Synthesis and antitumor activity evaluation in vitro of 4-aminoquinazoline derivatives containing 1,3,4-thiadiazole

Design, synthesis, and evaluation of antitumor activity of quinazoline derivatives containing different terminal segments of basic amine groups

Development of a Series of Novel 4-Anlinoquinazoline Derivatives Possessing Quinazoline Skeleton: Design, Synthesis, EGFR Kinase Inhibitory Efficacy, and Evaluation of Anticancer Activities in Vitro.

Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition

Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.

Combination of 4-Anilinoquinazoline, Arylurea and Tertiary Amine Moiety to Discover Novel Anticancer Agents.

Design, Synthesis, and in Vitro Antitumor Activity Evaluation of Novel 4‐pyrrylamino Quinazoline Derivatives

Synthesis of Selective PAK4 Inhibitors for Lung Metastasis of Lung Cancer and Melanoma Cells